SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Finally, the sodium/glucose cotransporter 2 (SGLT2) inhibitors are raising growing interest for the treatment of NAFLD, also considering their known beneficial effect on cardiovascular prevention in people with diabetes [245].